Here’s whether Bristol-Myers Squibb Co. (BMY) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.16% over 10 days); RSI 56 — healthy momentum range; strong 1-year return of +21.9%; 3-month momentum positive (+8.9%). Concerns: declining volume on rally — weak conviction (0.74x 30d avg). Currently 4.3% off its 52-week high. Score: +6/7.
BMY is in a confirmed uptrend, trading above both its 50-day ($59.86) and 200-day ($51.43) moving averages. An RSI of 56.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +21.9% compares to +35.1% for SPY (trailed the market by 13.2%).
$10,000 invested 1 year ago→ $12,190 today
vs. S&P 500 (SPY) — same period trailed market by 13.2%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($51.43)
✓Above 50-day MA ($59.86)
✓RSI(14) neutral zone (30–70) — currently 56.3
✓Positive return (+21.9%)
✓Within 10% of period high (−4.3%)
Period Range $60.17
$42.52$62.89
RSI (14) 56.3
0 · OversoldOverbought · 100
Key Metrics
Price$60.17
Period Return+21.9%
Period High$62.89
Period Low$42.52
Drawdown−4.3%
MA-50$59.86
MA-200$51.43
RSI (14)56.3
Avg Volume (30d)12.2M
vs. SPYtrailed by 13.2%
Return Rank#539 of 996
Trend Signals
Price is above the 200-day moving average ($51.43)